Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2010

View Archived Issues

Phase IIa data disclosed on tideglusib in Alzheimer's disease

Novartis reviews second quarter of 2010

EVP-0015962 improves cognitive deficit in mouse model of Alzheimer's disease

PDIP-38 is a candidate biomarker for progression of HPV-16-associated cervical dysplasia

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

Drug-targetable rearrangements of RAF kinase pathway members identified in prostate cancer

Repros Therapeutics to start low-dose study of Proellex

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

Enrollment begins in phase II MM-121 trial in breast cancer

NACI updates recommendations on rotavirus vaccination in Canada

University of Michigan claims new STAT-3 inhibitors

AiCuris discloses new anti-HIV agents

Algeta concludes manufacture and supply agreements for alpharadin

S/GSK-1265744 is active against RAL-resistant HIV isolates in vitro

Fresenius Medical Care expands its dialysis products business

FDA grants CBLB-502 fast track status for acute radiation syndrome

DSMB recommends completion of phase II FV-100 trial in shingles

NPS Pharma advances phase III trial of teduglutide in short bowel syndrome

ConjuChem Biotechnologies files for bankruptcy

CP-404 successfully completes pilot phase I study for obesity

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

Euthymics Bioscience acquires DOV Pharma and continues EB-1010 development

MDRNA shareholders approve Cequent acquisition and name change to Marina Biotech

Korean scientists discover new cyclic penta-depsipeptides

Sirtris Pharmaceuticals describes new SIRT modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.